Regional changes in intestinal permeability in cirrhosis are associated with mucosal bacteria.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
received:
31
05
2023
accepted:
02
06
2023
medline:
23
10
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
epublish
Résumé
Several complications of cirrhosis are theorized to result from the translocation of bacteria or their products across the intestinal epithelium. We aimed to assess epithelial permeability and associations with mucosal bacteria in patients with cirrhosis. We collected 247 duodenum, ileum, and colon biopsies from 58 consecutive patients with cirrhosis and 33 controls during clinically indicated endoscopies. Patients with cirrhosis were similarly aged to controls (60 vs. 58 y) and had a median Model for End-stage Liver Disease of 8 (interquartile range 7, 10). Biopsies underwent 16S rRNA-encoding gene amplicon sequencing to determine mucosal bacteria composition and transepithelial electrical resistance (TEER) to determine epithelial permeability. In the entire cohort, there were regional differences in TEER with the lowest TEER (ie, more permeable) in the ileum; duodenum TEER was 43% higher and colon TEER 20% higher than ileum TEER (ANOVA p = 0.0004). When comparing patients with cirrhosis and controls, both TEER (26% lower in cirrhosis, p = 0.006) and alpha diversity differed in the duodenum (27% lower in cirrhosis, p = 0.01) but not ileum or colon. A beta-binomial model found that 26 bacteria were significantly associated with TEER. Bifidobacteriaceae Bifidobacterium in duodenal mucosa was protective of epithelial permeability and future hospitalization for hepatic decompensation. Duodenal epithelial permeability was higher, and mucosal bacteria alpha diversity was lower in cirrhosis compared to controls, while no such differences were seen in the ileum or colon. Specific bacteria were associated with epithelial permeability and future hepatic decompensation.
Sections du résumé
BACKGROUND
Several complications of cirrhosis are theorized to result from the translocation of bacteria or their products across the intestinal epithelium. We aimed to assess epithelial permeability and associations with mucosal bacteria in patients with cirrhosis.
APPROACH AND RESULTS
We collected 247 duodenum, ileum, and colon biopsies from 58 consecutive patients with cirrhosis and 33 controls during clinically indicated endoscopies. Patients with cirrhosis were similarly aged to controls (60 vs. 58 y) and had a median Model for End-stage Liver Disease of 8 (interquartile range 7, 10). Biopsies underwent 16S rRNA-encoding gene amplicon sequencing to determine mucosal bacteria composition and transepithelial electrical resistance (TEER) to determine epithelial permeability. In the entire cohort, there were regional differences in TEER with the lowest TEER (ie, more permeable) in the ileum; duodenum TEER was 43% higher and colon TEER 20% higher than ileum TEER (ANOVA p = 0.0004). When comparing patients with cirrhosis and controls, both TEER (26% lower in cirrhosis, p = 0.006) and alpha diversity differed in the duodenum (27% lower in cirrhosis, p = 0.01) but not ileum or colon. A beta-binomial model found that 26 bacteria were significantly associated with TEER. Bifidobacteriaceae Bifidobacterium in duodenal mucosa was protective of epithelial permeability and future hospitalization for hepatic decompensation.
CONCLUSIONS
Duodenal epithelial permeability was higher, and mucosal bacteria alpha diversity was lower in cirrhosis compared to controls, while no such differences were seen in the ileum or colon. Specific bacteria were associated with epithelial permeability and future hepatic decompensation.
Identifiants
pubmed: 37756036
doi: 10.1097/HC9.0000000000000221
pii: 02009842-202310010-00035
pmc: PMC10531369
pii:
doi:
Substances chimiques
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.
Références
Appl Environ Microbiol. 2013 Sep;79(17):5112-20
pubmed: 23793624
Am J Physiol Gastrointest Liver Physiol. 2012 Sep 15;303(6):G675-85
pubmed: 22821944
Ann Appl Stat. 2020 Mar;14(1):94-115
pubmed: 32983313
J Clin Med. 2020 Aug 24;9(9):
pubmed: 32847083
J Microbiol Biotechnol. 2020 Oct 28;30(10):1480-1487
pubmed: 32807750
Gut. 2017 Apr;66(4):611-619
pubmed: 26887816
JCI Insight. 2020 May 7;5(9):
pubmed: 32302292
Clin Transl Gastroenterol. 2022 Oct 01;13(10):e00522
pubmed: 36000993
Sci Rep. 2015 Dec 22;5:18559
pubmed: 26692421
J Hepatol. 2014 May;60(5):940-7
pubmed: 24374295
Exp Physiol. 2017 Jul 1;102(7):791-803
pubmed: 28436589
JCI Insight. 2021 Nov 22;6(22):
pubmed: 34618688
Gut. 2020 Mar;69(3):513-522
pubmed: 31900289
Int J Mol Sci. 2021 Jul 28;22(15):
pubmed: 34360835
Nature. 2014 Sep 4;513(7516):59-64
pubmed: 25079328
J Hepatol. 2022 Feb;76(2):332-342
pubmed: 34571050
PLoS One. 2016 Aug 23;11(8):e0161635
pubmed: 27551722
Appl Environ Microbiol. 2009 Dec;75(23):7537-41
pubmed: 19801464
Pathogens. 2021 Apr 22;10(5):
pubmed: 33922308
ISME J. 2012 Jul;6(7):1415-26
pubmed: 22258098
J Hepatol. 2013 Jun;58(6):1125-32
pubmed: 23402745
Am J Physiol Gastrointest Liver Physiol. 2014 Jan;306(2):G147-53
pubmed: 24264047
Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6
pubmed: 23193283
Gut. 2019 Aug;68(8):1516-1526
pubmed: 31076401
Gut. 2014 Feb;63(2):262-71
pubmed: 23474421
J Cell Biol. 1986 Jun;102(6):2125-36
pubmed: 3711143
Infect Immun. 2015 Mar;83(3):934-41
pubmed: 25534943
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):605-616
pubmed: 31296969
Bioengineered. 2021 Dec;12(1):6354-6363
pubmed: 34511035
J Lab Autom. 2015 Apr;20(2):107-26
pubmed: 25586998
Nucleic Acids Res. 2014 Jan;42(Database issue):D633-42
pubmed: 24288368
Eur J Clin Invest. 2012 Apr;42(4):439-46
pubmed: 22023490
Gut. 2019 Apr;68(4):764-765
pubmed: 29618497
Physiol Rep. 2015 Mar;3(3):
pubmed: 25780093
J Gastroenterol Hepatol. 2015 Feb;30(2):268-78
pubmed: 25087692
Am J Gastroenterol. 2020 Nov;115(11):1891-1901
pubmed: 33156108
Gut. 2022 May;71(5):1020-1032
pubmed: 35105664
J Hepatol. 2013 May;58(5):911-21
pubmed: 23262249
J Physiol. 2015 Feb 1;593(3):585-99
pubmed: 25433076
Neurogastroenterol Motil. 2012 Jun;24(6):503-12
pubmed: 22583600
Gastroenterology. 2021 Jan;160(1):206-218.e13
pubmed: 32941879